Fzata, Inc.
Halethorpe
About Fzata, Inc.
Fzata’s capturing the “holy grail” of oral biologics with our transformational Bioengineered Probiotic Yeast Medicines (BioPYM) modality. With $17M in non-dilutive NIH funding, Fzata has developed a pipeline of drug candidates for gastrointestinal-related disorders. BioPYM platform uses live yeast as a ‘factory’ to make recombinant therapeutic biologics in the gut. Advantages over traditional biologics include: simple yeast manufacturing, no anti-drug antibody response, no toxicity, no refrigeration and no needles. BioPYM FZ002 first-in-human phase 1 clinical trial. for C. diff infection will be in 2023. Next is FZ006 for ulcerative colitis and Crohn's disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.0M
- Funding stage: Seed
- Last round: Grant (Sep 2024)
- Website: fzata.com
- Phone: +1 443 543 5040
Industries & Categories
Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/fzata-inc-2235142 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.